NIH | National Cancer Institute | NCI Wiki  

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Pihl, Todd (NIH/NCI) [C]

X
Unknown User (leblancak)
X

Otridge, John (NIH/NCI) [C]


X
Kim, Erika (NIH/NCI) [E]
X

Sommers, Connie (NIH/NCI) [E]

X
Debbie KnappX
Toby HechtX
Anju Singh
X
Unknown User (parchmentr)X

Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

Box Folder

https://nih.box.com/s/5wmrgl85z6fxpo3ldhanxzmmqq3ekfy7

Outstanding Action Items

Discussion items

ItemWhoTalking Points
Steering Committee Meeting UpdatesUnknown User (parchmentr)
  • Guest speaker, Daniel Promislow on Dog Aging Study that has been funded, interventional trial
  • Speakers will join the Steering Committee on the 20th.
ICDC Site Updates

Kuffel, Gina (NIH/NCI) [C]

  • Successful production release on September 16th
  • Site review
    • ICDC is in the queue for the user research study from the CRDC user research team, expected report back by December
    • MTA
ICDC Next Phase

Unknown User (hechtt)

  • Small group needed for brainstorming
DGAB UpdatesKuffel, Gina (NIH/NCI) [C]
  • Addressing the submission of data from other groups, candidate publication list
  • Contacting authors for Shaying's pan-cancer study

Minutes (Not Verbatim)

DK- Data may be coming into ICDC from the Promislow and Rod Page from Colorado State.

TH- In the Aging study are they looking at specific breeds?

DK- Several represented. Working heavily with the Broad and data made available there. The cancer data may be available to be deposited into ICDC.

EK- One of the reasons we pushed for user research on canine is we have a lot of flexibility to make improvements. It will be interesting to do this at this stage and then possibly again in the future. Please send relevant questions for the study if they exist.

RP- We may need NCI to take a look that the MTA once it is drafted. Claudia Hayward has been working with this on us.

TH- I can make arrangements for that.

RP- Not an acquisition, just a reimbursement.

TH- NCI should at least take a look and give their approval. Regarding tech transfer, will commercial companies use this data? Is there an issue with a commercial company using ICDC data to make a product? 

EK- Data use guidelines are coming soon.

TH- Keep these policies consistent with other data commons.

TH- Need to start seriously thinking about the next Task Order. We need a small group to brainstorm and present to the Executive Committee and then the Steering Committee. Not sure if Debbie can be involved because she is external. I propose myself, Connie, Erika, and Ralph. I'm not getting any feedback from anyone about what they think we should be doing. 

CS- Maybe include Elaine, to include a non-cancer perspective.

TH- Let's plan for mid-November. Can we talk more with John Otridge and determine his role. What about Anju? I will reach out to Anju.

TH- All authors working with canines will now know if they have additional data.

AL- We have many folks in the SC that may have pipelines that exist, others may be willing to share their pipelines.

CS- I have a grantee that we should talk with about sharing pipelen

AL- Not many people understand molecular implications of canine lymphoma, little cross-validation of IHc. Not fair to say they don't match, the right set of tools is needed. 30% of case load is Lymphoma. Such a diverse disease.



Action items